Epilepsy Trial, Recruiting NCT03233399 Sponsor: NYU Langone Health Condition: Epilepsy
Back to Epilepsy

Epilepsy Trial, Recruiting

NCT03233399
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Healthy volunteers who are fluent in English may be eligible to participate.
  • Patients who have been diagnosed with a psychogenic movement disorder (PMD) or psychogenic non-epileptic seizures (PNES) confirmed by a specialist neurologist may be eligible.
  • Patients whose treating neurologist does not expect them to need new or changed treatments for 3 to 6 months after the initial screening appointment may be eligible.

Who may not be able to join:

  • People who have a significant neurological condition that could affect the study results, as decided by the lead researcher.
  • People who have a long-term or worsening medical condition.
  • People who have any history of a brain injury or serious head trauma.
  • People who currently have a problem with substance misuse or dependence.
  • People who have a history of psychosis or another psychiatric condition that could affect the study results.
  • People who are pregnant.
  • People who have any metal or devices in their head, such as brain stimulators or metal fragments.
  • People who have any other implanted metal device in their body, such as a pacemaker, spinal cord stimulator, or vagus nerve stimulator.
  • People who have any other magnetic metal material in their body, including some dental prosthetics (confirm with trial site).
  • People who are taking certain antidepressants (tricyclic antidepressants), anti-seizure medications, or other brain-affecting drugs listed on a specific safety list (confirm with trial site).
  • People who have been diagnosed with an inflammatory or autoimmune condition in the last 6 months.
  • Patients with PMD or PNES who also have a diagnosed organic (physically caused) seizure disorder, including febrile or tonic-clonic seizures.
  • Patients with PMD or PNES who have another neurological condition such as stroke, fainting, or unexplained loss of consciousness.
  • Patients with PMD or PNES who have a serious or unstable physical illness.
  • Patients with PMD or PNES who have been diagnosed with dementia, or who score 24 or below on a standard memory and thinking test called the MoCA.
  • Patients with PMD or PNES who have experienced repeated visual hallucinations in the past 6 months.
  • Patients with PMD or PNES who have a history of significant uncontrollable head movements.
  • Patients with PMD or PNES who have any important abnormalities in their basic health measurements such as blood pressure, heart rate, or temperature.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Biyu He, MD, NYU Langone Health

Phone: (212) 263-0228

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
20 July 2017
Est. completion
1 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Changes in signal intensity measured using of tDCS; Changes in signal intensity measured during EEG recording; Changes in signal intensity measured during MEG

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov